‘Syn-Pharma’ launched to catalyse pharma innovation in North
The Northern Region Science & Technology Cluster, PI-RAHI, today launched its flagship initiative ‘Syn-Pharma’ at the Panjab University. The platform is designed to catalyse pharmaceutical and MedTech innovation across northern India through collaborative research, regulatory alignment and industry-academia partnerships.
The launch event was inaugurated by Dr Rajeev Singh Raghuvanshi, Drugs Controller General of India, who commended the initiative and addressed the gathering of stakeholders from academia, industry and policy bodies. In his keynote address, Dr Raghuvanshi emphasised the need for innovation to be rooted in quality. “Innovation must serve the purpose of improving drug quality. Quality value should be in the driver’s seat, not profit. Value must be important instead of volume,” he added.
Highlighting India’s unique position in the global pharmaceutical landscape, he added, “The country is at an interesting crossroad, and the next six years will be crucial. The world is watching and waiting for India to deliver quality medicines at affordable prices.”
Delivering the presidential address, PU Vice-Chancellor and Chairperson of PI-RAHI Renu Vig reiterated the critical role of academic institutions in bridging the gap with industry. Nodal Officer for the PI-RAHI cluster from the office of the Principal Scientific Adviser to the Government of India, Vishal Chaoudhary; Joint Director of NABL, Pankaj Goyal, and former PU VC Arun Grover also addressed the gathering.
At the event, PI-RAHI unveiled two major initiatives under the ‘Syn-Pharma’ banner.
Three start-ups mentored by PI-RAHI under the PSCST’s SHE 3.0 initiative were also felicitated for their pioneering work.
Unlock Exclusive Insights with The Tribune Premium
Take your experience further with Premium access.
Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Already a Member? Sign In Now